Scarica l'app Stockscreener
82.47
1.14%
-0.95
Dopo l'orario di chiusura:
82.47
Intra Cellular Therapies Inc Borsa (ITCI) Ultime notizie
Entropy Technologies LP Acquires Shares of 7,116 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Simplify Asset Management Inc. Increases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-cellular therapies president sells $3.69 million in stock - Investing.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Position Increased by Aigen Investment Management LP - MarketBeat
FMR LLC Reduces Stake in Intra-Cellular Therapies Inc - GuruFocus.com
Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 12-Month HighTime to Buy? - MarketBeat
Lisanti Capital Growth LLC Sells 24,760 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular bolsters Caplyta data with another Phase III win - MSN
Principal Financial Group Inc. Acquires 18,865 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
TimesSquare Capital Management LLC Grows Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
M&G Plc Invests $9.08 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High of $90.37 - Investing.com India
Intra-Cellular Therapies Stock Hits All-Time High of $90.37 By Investing.com - Investing.com UK
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress - The Manila Times
Lifespeak Inc (LSPK-T) QuotePress Release - The Globe and Mail
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26% - Simply Wall St
Intra-Cellular Therapies Inc (ITCI) Trading 3.56% Higher on Nov 6 - GuruFocus.com
Positive Phase III results for Intra-Cellular’s Caplyta in schizophrenia - The Pharma Letter
Intra-Cellular Therapies Announces Positive Topline Results - GlobeNewswire
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63% - Benzinga
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid market expansion - Investing.com India
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial - Reuters
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia - The Manila Times
Harbor Capital Advisors Inc. Boosts Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews - Benzinga
Intra-Cellular Therapies (NASDAQ:ITCI) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for ITCI Earnings - MarketBeat
Emerald Advisers LLC Acquires 48,705 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Net Present Value Model: Intra-Cellular Therapies Inc’s Lenrispodun phosphate - GlobalData
(ITCI) Technical Pivots with Risk Controls - Stock Traders Daily
Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results - Yahoo Finance
Intra-Cellular price target raised to $135 from $130 at Cantor Fitzgerald - MSN
FY2027 Earnings Estimate for ITCI Issued By Leerink Partnrs - MarketBeat
Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
abrdn plc Has $18.36 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates - MSN
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Large Decrease in Short Interest - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High at $85 By Investing.com - Investing.com Australia
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Call Transcript - Insider Monkey
Intra-Cellular: Q3 Earnings Snapshot - The Pioneer
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales - MSN
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $96.62 Average Target Price from Brokerages - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High at $85 - Investing.com India
Intra-Cellular Therapies Reports Strong Q3 Growth - TipRanks
Intra-Cellular stock target raised on Caplyta sales outlook By Investing.com - Investing.com Canada
Intra-Cellular jumps on Q3 beat as Caplyta outlook brightens - MSN
Intra-Cellular Therapies Q3 2024 Earnings Preview - MSN
Intra-Cellular stock jumps on Caplyta outlook (ITCI:NASDAQ) - Seeking Alpha
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year HighStill a Buy? - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
0.54%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):